US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

34.61

+0.45001.32%

Post-market: 34.610.00000.00%19:30 EDT

Volume:440.67K

Turnover:15.17M

Market Cap:1.12B

PE:-11.58

High:35.73

Open:33.83

Low:33.13

Close:34.16

52wk High:50.16

52wk Low:14.32

Shares:32.26M

Float Shares:21.62M

Volume Ratio:1.11

T/O Rate:2.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:3.36

PE(LYR):-11.05

Loading ...

Overview Company News Filings

LB Pharmaceuticals Releases Update on Nova-2 Phase 3 Schizophrenia Trial Timeline

Lb Pharmaceuticals - Topline Data from Phase 2 Trial in Adjunctive Mdd Expected in H1 2029

THOMSON REUTERS

Lb Pharmaceuticals - Expects Cash Runway into Q2 2029

THOMSON REUTERS

Lb Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 Nova-2 Trial of Lb-102 in Schizophrenia

THOMSON REUTERS

Lb Pharmaceuticals - to Report Phase 3 Nova-2 Topline Results in H1 2027

THOMSON REUTERS

Lb Pharmaceuticals - Topline Data from Phase 2 Illuminate-1 in Bipolar Depression Expected in Q1 2028

THOMSON REUTERS

Lb Pharmaceuticals Inc : Bmo Initiates Coverage with Outperform Rating; Target Price $46

THOMSON REUTERS

LB Pharmaceuticals Initiated at Outperform by BMO Capital

LB Pharmaceuticals Grants SVP Zergebel Option for 75,000 Shares at $32.95 Under NASDAQ Inducement Rule

Lb Pharmaceuticals Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(c)(4)

LB Pharmaceuticals Initiated at Outperform by Wolfe Research

Lb Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

THOMSON REUTERS

Press Release: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from H.C. Wainwright

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

LB Pharmaceuticals CMO Anna Eramo steps down, shifts to advisor role

LB Pharmaceuticals Stockholders Approve Directors and Auditor

LB Pharmaceuticals shareholders elect Class I directors at annual meeting

H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/LBRX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":34.61,"timestamp":1791489600000,"preClose":34.16,"halted":0,"volume":440665,"hourTrading":{"tag":"盘后","latestPrice":34.61,"preClose":34.61,"latestTime":"19:30 EDT","volume":3570,"amount":123557.7,"timestamp":1791502204109,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013173302107728421,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Closed","change":0.45,"latestTime":"10-08 16:00:00 EDT","open":33.83,"high":35.725,"low":33.13,"amount":15170309.053425,"amplitude":0.075966,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":5,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":34.16,"preHourTrading":{"tag":"盘前","latestPrice":33.48,"preClose":34.16,"latestTime":"09:09 EDT","volume":410,"amount":13726.8,"timestamp":1791464948535,"change":-0.68,"changeRate":-0.019906,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.61,"preClose":34.61,"latestTime":"19:30 EDT","volume":3570,"amount":123557.7,"timestamp":1791502204109,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.112751,"impliedVol":0.6203,"impliedVolPercentile":0.2283},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":1.112751,"shares":32259175,"dividePrice":0,"high":35.725,"amplitude":0.075966,"preClose":34.16,"low":33.13,"week52Low":14.3166,"pbRate":"3.36","week52High":50.16,"institutionHeld":0,"latestPrice":34.61,"eps":-2.988,"divideRate":0,"volume":440665,"delay":0,"ttmEps":-2.988,"open":33.83,"prevYearClose":22.26,"prevWeekClose":36.99,"prevMonthClose":38.38,"prevQuarterClose":38.38,"fiveDayClose":37.28,"twentyDayClose":46.25,"sixtyDayClose":32.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.5455,"hold":0.0909,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1791259200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-10-07","current":-11.582999,"percent":0.850746,"low":-37.407457,"twenty":-31.668276,"median":-23.675741,"eighty":-16.011936,"high":-0.410019,"avg":-23.387475,"sd":7.599082,"marketCap":1105199335},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-28","current":-18.029899,"twenty":-31.988483,"median":-24.686825,"eighty":-17.939919,"marketCap":1544891890},{"date":"2026-09-04","current":-17.890599,"twenty":-31.950812,"median":-24.595973,"eighty":-17.81229,"marketCap":1532955996},{"date":"2026-09-11","current":-17.412462,"twenty":-31.886233,"median":-24.257328,"eighty":-17.792713,"marketCap":1491986843},{"date":"2026-09-18","current":-15.865106,"twenty":-31.84587,"median":-23.934856,"eighty":-17.412462,"marketCap":1359401634},{"date":"2026-09-25","current":-14.231158,"twenty":-31.724783,"median":-23.892916,"eighty":-16.881618,"marketCap":1219396815},{"date":"2026-10-02","current":-14.035386,"twenty":-31.684421,"median":-23.764083,"eighty":-16.185119,"marketCap":1202622044},{"date":"2026-10-07","current":-12.898399,"twenty":-31.668276,"median":-23.675741,"eighty":-16.011936,"marketCap":1105199335}],"updateTime":1791515739375},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653875778","title":"LB Pharmaceuticals Releases Update on Nova-2 Phase 3 Schizophrenia Trial Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2653875778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653875778?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:04","pubTimestamp":1784721878,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timelineLB Pharmaceuticals posted a press release accelerating expected topline timing for Phase 3 NOVA-2 data for LB-102 in sc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL7Nm80f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BCDF","LU2095319765.USD","LBRX","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","NDAQ","IE00B64PRP62.GBP","BK4007","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757466","title":"Lb Pharmaceuticals - Topline Data from Phase 2 Trial in Adjunctive Mdd Expected in H1 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757466?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757457","title":"Lb Pharmaceuticals - Expects Cash Runway into Q2 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757457?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757430","title":"Lb Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 Nova-2 Trial of Lb-102 in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757430?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757102","title":"Lb Pharmaceuticals - to Report Phase 3 Nova-2 Topline Results in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757102?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653482757","title":"Lb Pharmaceuticals - Topline Data from Phase 2 Illuminate-1 in Bipolar Depression Expected in Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2653482757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653482757?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:00","pubTimestamp":1784721602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA4PWVRD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653427942","title":"Lb Pharmaceuticals Inc : Bmo Initiates Coverage with Outperform Rating; Target Price $46","url":"https://stock-news.laohu8.com/highlight/detail?id=2653427942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653427942?lang=en_us&edition=fundamental","pubTime":"2026-07-21 18:49","pubTimestamp":1784630990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N0S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653437273","title":"LB Pharmaceuticals Initiated at Outperform by BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2653437273","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653437273?lang=en_us&edition=fundamental","pubTime":"2026-07-21 17:43","pubTimestamp":1784626980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings(END) Dow Jones NewswiresJuly 21, 2026 05:43 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","LBRX","BMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137199","title":"LB Pharmaceuticals Grants SVP Zergebel Option for 75,000 Shares at $32.95 Under NASDAQ Inducement Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137199?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:39","pubTimestamp":1783715982,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals grants SVP Zergebel option for 75,000 shares at $32.95 under Nasdaq inducement ruleLB Pharmaceuticals granted new SVP Clinical Operations Christopher Zergebel a stock option for 75,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL21tbY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LBRX","BK4112","LU2095319765.USD","BK4007","IE00BKPKM429.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137975","title":"Lb Pharmaceuticals Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137975?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:38","pubTimestamp":1783715938,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nTUA9WQGXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137122","title":"Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137122?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:38","pubTimestamp":1783715880,"startTime":"0","endTime":"0","summary":"NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (\"LB Pharmaceuticals\" or the \"Company\") (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior V","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPIQ","NDX","TQQY","QQQ","QDTE","TQQQ","NVIW.SI","LB","BK4233","PSQ","SQQQ",".IXIC","QQQJ","QQQM","QQQY","BK4213","ONEQ","BK4007","QID","NQmain","QYLG","QQQA","QQQE","IYW","MNQmain","FTEC","QLD","LBRX","TECS","JEPQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981162","title":"LB Pharmaceuticals Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981162?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:50","pubTimestamp":1783421400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 06:50 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647055397","title":"Lb Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2647055397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647055397?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:00","pubTimestamp":1782820802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3KC6M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647055312","title":"Press Release: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2647055312","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647055312?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:00","pubTimestamp":1782820800,"startTime":"0","endTime":"0","summary":"NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (\"LB Pharmaceuticals\" or the \"Company\") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4213","BK4007","LB","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646280811","title":"LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2646280811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646280811?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:36","pubTimestamp":1782390985,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $45.00. Selvaraju covers ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","LB","BK4233","LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643078157","title":"Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2643078157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643078157?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:30","pubTimestamp":1781562609,"startTime":"0","endTime":"0","summary":"Clear Street keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clear-street-says-neumora-failed-trial-does-not-impact-lb-pharmaceuticals-lb-102-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clear-street-says-neumora-failed-trial-does-not-impact-lb-pharmaceuticals-lb-102-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NMRA","BK4233","LBRX","LB","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642757934","title":"LB Pharmaceuticals CMO Anna Eramo steps down, shifts to advisor role","url":"https://stock-news.laohu8.com/highlight/detail?id=2642757934","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642757934?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:17","pubTimestamp":1781122645,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals’ Chief Medical Officer Anna Eramo resigned effective June 15, 2026.Eramo will transition to an advisor role for personal reasons.A search is underway for a replacement; existing clinical teams will oversee ongoing trials.The change is not expected to materially affect clinical development activities or previously disclosed clinical milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL4xhGZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642349060","title":"LB Pharmaceuticals Stockholders Approve Directors and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642349060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642349060?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:57","pubTimestamp":1781038629,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ( ($LBRX) ) has shared an announcement. LB Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","BK4213","BK4007","LB","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642492028","title":"LB Pharmaceuticals shareholders elect Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642492028","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642492028?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:06","pubTimestamp":1781035584,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals held its annual shareholder meeting on June 3, 2026.Shareholders backed the selection of three Class I directors for new three-year terms running to the 2029 annual meeting.Investors ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9jWPkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435705","title":"H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435705?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:35","pubTimestamp":1780940148,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}